Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 627


A common genetic variant in 19q13·3 is associated with outcome of multiple myeloma patients treated with Total Therapy 2 and 3.

Erickson SW, Stephens OW, Chavan SS, Epstein J, Barlogie B, Heuck CJ, Vangsted AJ.

Br J Haematol. 2015 Nov 16. doi: 10.1111/bjh.13830. [Epub ahead of print] No abstract available.


Primary myeloma interaction and growth in coculture with healthy donor hematopoietic bone marrow.

Bam R, Khan S, Ling W, Randal SS, Li X, Barlogie B, Edmondson R, Yaccoby S.

BMC Cancer. 2015 Nov 6;15:864. doi: 10.1186/s12885-015-1892-7.


The clinical value of molecular subtyping multiple myeloma using gene expression profiling.

Weinhold N, Heuck C, Rosenthal A, Thanendrarajan S, Stein C, Van Rhee FV, Zangari M, Hoering A, Tian E, Davies FE, Barlogie B, Morgan GJ.

Leukemia. 2015 Nov 3. doi: 10.1038/leu.2015.309. [Epub ahead of print]


Prospective analysis of antigen-specific immunity, stem cell antigens and immune checkpoints in monoclonal gammopathy.

Dhodapkar MV, Sexton R, Das R, Dhodapkar KM, Zhang L, Sundaram R, Soni S, Crowley JJ, Orlowski RZ, Barlogie B.

Blood. 2015 Oct 14. pii: blood-2015-03-632919. [Epub ahead of print]


American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma.

Giralt S, Garderet L, Durie B, Cook G, Gahrton G, Bruno B, Hari P, Lokhorst H, McCarthy P, Krishnan A, Sonneveld P, Goldschmidt H, Jagannath S, Barlogie B, Mateos M, Gimsing P, Sezer O, Mikhael J, Lu J, Dimopoulos M, Mazumder A, Palumbo A, Abonour R, Anderson K, Attal M, Blade J, Bird J, Cavo M, Comenzo R, de la Rubia J, Einsele H, Garcia-Sanz R, Hillengass J, Holstein S, Johnsen HE, Joshua D, Koehne G, Kumar S, Kyle R, Leleu X, Lonial S, Ludwig H, Nahi H, Nooka A, Orlowski R, Rajkumar V, Reiman A, Richardson P, Riva E, San Miguel J, Turreson I, Usmani S, Vesole D, Bensinger W, Qazilbash M, Efebera Y, Mohty M, Gasparreto C, Gajewski J, LeMaistre CF, Bredeson C, Moreau P, Pasquini M, Kroeger N, Stadtmauer E.

Biol Blood Marrow Transplant. 2015 Dec;21(12):2039-51. doi: 10.1016/j.bbmt.2015.09.016. Epub 2015 Sep 30. Review.


Common genetic variants in 11q13.3 and 9q22.33 are associated with molecular subgroups of multiple myeloma.

Erickson SW, Stephens OW, Chavan SS, Tian E, Epstein J, Barlogie B, Heuck CJ, Vangsted AJ.

Leukemia. 2015 Aug 26. doi: 10.1038/leu.2015.238. [Epub ahead of print] No abstract available.


Inhibiting MEK in MAPK pathway-activated myeloma.

Heuck CJ, Jethava Y, Khan R, van Rhee F, Zangari M, Chavan S, Robbins K, Miller SE, Matin A, Mohan M, Ali SM, Stephens PJ, Ross JS, Miller VA, Davies F, Barlogie B, Morgan G.

Leukemia. 2015 Jul 31. doi: 10.1038/leu.2015.208. [Epub ahead of print] No abstract available.


Allelic mutations in noncoding genomic sequences construct novel transcription factor binding sites that promote gene overexpression.

Tian E, Børset M, Sawyer JR, Brede G, Våtsveen TK, Hov H, Waage A, Barlogie B, Shaughnessy JD Jr, Epstein J, Sundan A.

Genes Chromosomes Cancer. 2015 Nov;54(11):692-701. doi: 10.1002/gcc.22280. Epub 2015 Jul 29.


Using a latent class model to refine risk stratification in multiple myeloma.

Qu P, Barlogie B, Crowley J.

Stat Med. 2015 Sep 20;34(21):2971-80. doi: 10.1002/sim.6557. Epub 2015 Jun 17.


Four genes predict high risk of progression from smoldering to symptomatic multiple myeloma (SWOG S0120).

Khan R, Dhodapkar M, Rosenthal A, Heuck C, Papanikolaou X, Qu P, van Rhee F, Zangari M, Jethava Y, Epstein J, Yaccoby S, Hoering A, Crowley J, Petty N, Bailey C, Morgan G, Barlogie B.

Haematologica. 2015 Sep;100(9):1214-21. doi: 10.3324/haematol.2015.124651. Epub 2015 May 28.


Evidence of an epigenetic origin for high-risk 1q21 copy number aberrations in multiple myeloma.

Sawyer JR, Tian E, Heuck CJ, Johann DJ, Epstein J, Swanson CM, Lukacs JL, Binz RL, Johnson M, Sammartino G, Zangari M, Davies FE, van Rhee F, Morgan GJ, Barlogie B.

Blood. 2015 Jun 11;125(24):3756-9. doi: 10.1182/blood-2015-03-632075. Epub 2015 May 5.


Removing batch effects from purified plasma cell gene expression microarrays with modified ComBat.

Stein CK, Qu P, Epstein J, Buros A, Rosenthal A, Crowley J, Morgan G, Barlogie B.

BMC Bioinformatics. 2015 Feb 25;16:63. doi: 10.1186/s12859-015-0478-3.


Fulminant onset of acute leukemia from normal hematopoiesis within 3 months of follow up for multiple myeloma treated with total therapy protocols.

Singh ZN, Jethava Y, Post GR, Alapat D, Sawyer J, Waheed S, Nair B, Usmani SZ, Bailey C, Petty N, Van Rhee F, Barlogie B.

Clin Case Rep. 2015 Mar;3(3):183-92. doi: 10.1002/ccr3.180. Epub 2015 Feb 13.


The flow cytometry-defined light chain cytoplasmic immunoglobulin index and an associated 12-gene expression signature are independent prognostic factors in multiple myeloma.

Papanikolaou X, Alapat D, Rosenthal A, Stein C, Epstein J, Owens R, Yaccoby S, Johnson S, Bailey C, Heuck C, Tian E, Joiner A, van Rhee F, Khan R, Zangari M, Jethava Y, Waheed S, Davies F, Morgan G, Barlogie B.

Leukemia. 2015 Aug;29(8):1713-20. doi: 10.1038/leu.2015.65. Epub 2015 Mar 10.


Renal insufficiency retains adverse prognostic implications despite renal function improvement following Total Therapy for newly diagnosed multiple myeloma.

Khan R, Apewokin S, Grazziutti M, Yaccoby S, Epstein J, van Rhee F, Rosenthal A, Waheed S, Usmani S, Atrash S, Kumar S, Hoering A, Crowley J, Shaughnessy JD Jr, Barlogie B.

Leukemia. 2015 May;29(5):1195-201. doi: 10.1038/leu.2015.15. Epub 2012 Feb 2.


Role of magnetic resonance imaging in the management of patients with multiple myeloma: a consensus statement.

Dimopoulos MA, Hillengass J, Usmani S, Zamagni E, Lentzsch S, Davies FE, Raje N, Sezer O, Zweegman S, Shah J, Badros A, Shimizu K, Moreau P, Chim CS, Lahuerta JJ, Hou J, Jurczyszyn A, Goldschmidt H, Sonneveld P, Palumbo A, Ludwig H, Cavo M, Barlogie B, Anderson K, Roodman GD, Rajkumar SV, Durie BG, Terpos E.

J Clin Oncol. 2015 Feb 20;33(6):657-64. doi: 10.1200/JCO.2014.57.9961. Epub 2015 Jan 20.


Cardiac complications in relapsed and refractory multiple myeloma patients treated with carfilzomib.

Atrash S, Tullos A, Panozzo S, Bhutani M, Van Rhee F, Barlogie B, Usmani SZ.

Blood Cancer J. 2015 Jan 16;5:e272. doi: 10.1038/bcj.2014.93. No abstract available.


Ex vivo-expanded natural killer cells demonstrate robust proliferation in vivo in high-risk relapsed multiple myeloma patients.

Szmania S, Lapteva N, Garg T, Greenway A, Lingo J, Nair B, Stone K, Woods E, Khan J, Stivers J, Panozzo S, Campana D, Bellamy WT, Robbins M, Epstein J, Yaccoby S, Waheed S, Gee A, Cottler-Fox M, Rooney C, Barlogie B, van Rhee F.

J Immunother. 2015 Jan;38(1):24-36. doi: 10.1097/CJI.0000000000000059.


Curing myeloma at last: defining criteria and providing the evidence.

Barlogie B, Mitchell A, van Rhee F, Epstein J, Morgan GJ, Crowley J.

Blood. 2014 Nov 13;124(20):3043-51. doi: 10.1182/blood-2014-07-552059. Epub 2014 Oct 7.


Phase II study of pomalidomide in high-risk relapsed and refractory multiple myeloma.

Usmani SZ, Zhang Q, Stratton K, Qu P, Yaccoby S, Hansen E, Steward D, Panozzo S, Petty N, Hoering A, Waheed S, Van Rhee F, Crowley J, Barlogie B.

Leukemia. 2014 Dec;28(12):2413-5. doi: 10.1038/leu.2014.248. Epub 2014 Aug 25. No abstract available.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk